Fabrizio Bianchi has several years of research experience in the field of cancer genomics, particularly in lung cancer. In 2004, he was the first to characterize the gene expression profile through microarray technology of early-diagnosed asymptomatic lung cancer detected by Low-dose computed tomography (LD-CT). He demonstrated that tumors detected by LD-CT have a very similar expression profile compared to more advanced tumors. At that time this was a breakthrough, since malignancy of LD-CT asymptomatic tumors had not been clearly ascertained and there were many criticisms about the effectiveness of LD-CT to detect lung cancer. Subsequently, in 2007, through the development of a novel 'integrated' approach for gene expression profiling analysis he was able to identify novel mRNA-based prognostic biomarkers for stage I lung cancer, where current diagnostic tools do not allow precise prognostic evaluation. More recently, he focused on the field of micro-RNA research, particularly for the identification of serum circulating miRNAs for the early diagnosis of lung cancer. This allowed identifying a powerful method for serum miRNA detection and discovering of miRNA serum biomarkers for lung cancer early detection, the miR-Test. Dr. Bianchi is an active member of AACR, of EACR, of IASLC and and of the Italian Society for Cancer Research (SIC) where he holds the position of secretary and executive board member.